{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:19:25Z","timestamp":1786119565577,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/wco.0b013e32833d7367","type":"journal-article","created":{"date-parts":[[2010,7,21]],"date-time":"2010-07-21T07:09:40Z","timestamp":1279696180000},"page":"496-501","source":"Crossref","is-referenced-by-count":2,"title":["Therapy update in nerve, neuromuscular junction and myopathic disorders"],"prefix":"10.1097","volume":"23","author":[{"given":"Hamid","family":"Sadeghian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil I","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210206","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1474-4422(09)70110-3","article-title":"Diagnosis, natural history, and management of Charcot-Marie-Tooth disease","volume":"8","author":"Pareyson","year":"2009","journal-title":"Lancet Neurol"},{"key":"R2-9-20210206","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nm1023","article-title":"Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease","volume":"10","author":"Passage","year":"2004","journal-title":"Nat Med"},{"key":"R3-9-20210206","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1474-4422(09)70108-5","article-title":"Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomized, double-blind, placebo-controlled, safety and efficacy trial","volume":"8","author":"Burns","year":"2009","journal-title":"Lancet Neurol"},{"key":"R4-9-20210206","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1474-4422(09)70260-1","article-title":"Effect of ascorbic acid in patients with Charcot-Marie-Tooth type 1A: a multicenter, randomized, double-blind, placebo controlled trial","volume":"8","author":"Micallef","year":"2009","journal-title":"Lancet Neurol"},{"key":"R5-9-20210206","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1468-1331.2006.01278.x","article-title":"EFNS\/PNS guideline on management of chronic inflammatory polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society","volume":"13","author":"Hughes","year":"2006","journal-title":"Eur J Neurol"},{"key":"R6-9-20210206","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1474-4422(10)70021-1","article-title":"Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomized, controlled trial","volume":"9","author":"van Schaik","year":"2010","journal-title":"Lancet Neurol"},{"key":"R7-9-20210206","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/jnnp.2009.177576","article-title":"Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy.","volume":"81","author":"Bedi","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R8-9-20210206","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000282734","article-title":"Multifocal motor neuropathy: update on clinical characteristics, pathophysiological concepts and therapeutic options","volume":"63","author":"Meuth","year":"2010","journal-title":"Eur Neurol"},{"key":"R9-9-20210206","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s00415-009-0130-0","article-title":"IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up","volume":"256","author":"Baumann","year":"2009","journal-title":"J Neurol"},{"key":"R10-9-20210206","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/WNL.0b013e3181d5279e","article-title":"Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial","volume":"74","author":"Pace","year":"2010","journal-title":"Neurology"},{"key":"R12-9-20210206","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jnnp.2008.144980","article-title":"Immunosuppressant drugs for myasthenia gravis","volume":"80","author":"Hart","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R13-9-20210206","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1405.000","article-title":"Tacrolimus for myasthenia gravis: a clinical study of 212 patients","volume":"1132","author":"Ponseti","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"R14-9-20210206","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.21462","article-title":"Factors associated with response to calcineurin inhibitors in myasthenia gravis","volume":"41","author":"Nagane","year":"2010","journal-title":"Muscle Nerve"},{"key":"R15-9-20210206","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis.","volume":"71","year":"2008","journal-title":"Neurology"},{"key":"R16-9-20210206","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"R17-9-20210206","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"key":"R18-9-20210206","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve"},{"key":"R19-9-20210206","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1212\/01.wnl.0000267884.39468.7a","article-title":"Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase","volume":"69","author":"Argov","year":"2007","journal-title":"Neurology"},{"key":"R20-9-20210206","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/WCO.0b013e32832f15fa","article-title":"Management of myasthenic conditions: nonimmune issues","volume":"22","author":"Argov","year":"2009","journal-title":"Curr Opin Neurol"},{"key":"R21-9-20210206","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mus.21422","article-title":"3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS","volume":"40","author":"Oh","year":"2009","journal-title":"Muscle Nerve"},{"key":"R22-9-20210206","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","article-title":"A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome","volume":"54","author":"Sanders","year":"2000","journal-title":"Neurology"},{"key":"R23-9-20210206","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1212\/01.wnl.0000167132.35865.31","article-title":"Congenital endplate acetylcholinesterase deficiency responsive to ephedrine","volume":"65","author":"Bestue-Cardiel","year":"2005","journal-title":"Neurology"},{"key":"R24-9-20210206","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1126\/science.1130837","article-title":"Dok-7 mutations underlie a neuromuscular junction synaptopathy","volume":"313","author":"Beeson","year":"2006","journal-title":"Science"},{"key":"R25-9-20210206","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.nmd.2009.09.008","article-title":"Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations","volume":"19","author":"Schara","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"R26-9-20210206","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1212\/WNL.0b013e3181dd43bf","article-title":"Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7","volume":"74","author":"Lashley","year":"2010","journal-title":"Neurology"},{"key":"R27-9-20210206","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1212\/01.WNL.0000061483.11417.1B","article-title":"Treatment of slow-channel congenital myasthenic syndrome with fluoxetine","volume":"60","author":"Harper","year":"2003","journal-title":"Neurology"},{"key":"R28-9-20210206","first-page":"480","article-title":"Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome","volume":"43","author":"Harper","year":"1998","journal-title":"Neurology"},{"key":"R29-9-20210206","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/jnnp.2008.169375","article-title":"Evaluation and treatment of inflammatory myopathies","volume":"80","author":"Amato","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R30-9-20210206","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/jnnp.2009.173823","article-title":"Inclusion body myositis: old and new concepts","volume":"80","author":"Amato","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R31-9-20210206","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"R32-9-20210206","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","article-title":"Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy","volume":"320","author":"Mendell","year":"1989","journal-title":"N Engl J Med"},{"key":"R33-9-20210206","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"R34-9-20210206","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1212\/01.wnl.0000306309.85301.e2","article-title":"Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D","volume":"71","author":"Rodino-Klapac","year":"2008","journal-title":"Neurology"},{"key":"R35-9-20210206","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.21732","article-title":"Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins","volume":"66","author":"Mendell","year":"2009","journal-title":"Ann Neurol"},{"key":"R36-9-20210206","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1056\/NEJMoa073108","article-title":"Local dystrophin restoration with antisense oligonucleotide PRO051","volume":"357","author":"van Deutekom","year":"2007","journal-title":"N Engl J Med"},{"key":"R37-9-20210206","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol"},{"key":"R38-9-20210206","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/archneurol.2008.540","article-title":"A renaissance for antisense oligonucleotide drugs in neurology","volume":"66","author":"Yokota","year":"2009","journal-title":"Arch Neurol"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/WCO.0b013e32833d7367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:27:02Z","timestamp":1786040822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00019052-201010000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e32833d7367","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}